The effect of epidermal growth factor receptor (EGFR) expression on in vivo growth of rat C6 glioma cells

R. A. Fenstermaker, J. Capala, R. F. Barth, A. Hujer, Hsing-Jien Kung, D. M. Kaetzel

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

The discovery of EGFR gene amplification in glioblastoma multiforme has prompted interest in experimental therapies to target the receptor on brain tumor cells. To develop an animal model for in vivo study of such strategies, we transfected C6 glioma cells with a plasmid containing the neomycin resistance gene and the human EGFR gene under the control of the glucocorticoid-inducible MMTV promoter. Following selection with G418, individual clones that expressed EGFR at high levels were selected. Kinetics of EGF binding fit a dual site model indicating the presence of both high (K(A) = 2.5 x 109 M-1) and low (K(A) = 3.3 x 107 M-1) affinity receptors. To assess growth in vivo, graded numbers of either wild-type or transfected cells were implanted into the brains of CD Fischer 344 rats. No differences in survival were observed between groups of animals injected with either wild-type or transfected cells at inocula of 103 or 104 respectively. In addition, one-third of animals (7/21) challenged with 105 or 106 transfected cells survived > 50 days compared to O% of animals (0/12) challenged with 105 or 106 wild-type cells. Such an effect suggests greater immunogenicity of transfected cells, but only at the larger inocula. Since C6 glioma cells will grow in both outbred and inbred strains, our model should have a number of applications including the in vivo study of EGFR targeting for glioma therapy.

Original languageEnglish (US)
JournalLeukemia
Volume9
Issue numberSUPPL. 1
StatePublished - 1995
Externally publishedYes

Fingerprint

Epidermal Growth Factor Receptor
Glioma
Growth
erbB-1 Genes
Investigational Therapies
Neomycin
Gene Amplification
Inbred F344 Rats
Glioblastoma
Epidermal Growth Factor
Brain Neoplasms
Glucocorticoids
Plasmids
Animal Models
Clone Cells
Survival
Brain
Genes

ASJC Scopus subject areas

  • Cancer Research
  • Hematology

Cite this

Fenstermaker, R. A., Capala, J., Barth, R. F., Hujer, A., Kung, H-J., & Kaetzel, D. M. (1995). The effect of epidermal growth factor receptor (EGFR) expression on in vivo growth of rat C6 glioma cells. Leukemia, 9(SUPPL. 1).

The effect of epidermal growth factor receptor (EGFR) expression on in vivo growth of rat C6 glioma cells. / Fenstermaker, R. A.; Capala, J.; Barth, R. F.; Hujer, A.; Kung, Hsing-Jien; Kaetzel, D. M.

In: Leukemia, Vol. 9, No. SUPPL. 1, 1995.

Research output: Contribution to journalArticle

Fenstermaker, RA, Capala, J, Barth, RF, Hujer, A, Kung, H-J & Kaetzel, DM 1995, 'The effect of epidermal growth factor receptor (EGFR) expression on in vivo growth of rat C6 glioma cells', Leukemia, vol. 9, no. SUPPL. 1.
Fenstermaker, R. A. ; Capala, J. ; Barth, R. F. ; Hujer, A. ; Kung, Hsing-Jien ; Kaetzel, D. M. / The effect of epidermal growth factor receptor (EGFR) expression on in vivo growth of rat C6 glioma cells. In: Leukemia. 1995 ; Vol. 9, No. SUPPL. 1.
@article{b54bba21b0db479497cc13ea95dd47e2,
title = "The effect of epidermal growth factor receptor (EGFR) expression on in vivo growth of rat C6 glioma cells",
abstract = "The discovery of EGFR gene amplification in glioblastoma multiforme has prompted interest in experimental therapies to target the receptor on brain tumor cells. To develop an animal model for in vivo study of such strategies, we transfected C6 glioma cells with a plasmid containing the neomycin resistance gene and the human EGFR gene under the control of the glucocorticoid-inducible MMTV promoter. Following selection with G418, individual clones that expressed EGFR at high levels were selected. Kinetics of EGF binding fit a dual site model indicating the presence of both high (K(A) = 2.5 x 109 M-1) and low (K(A) = 3.3 x 107 M-1) affinity receptors. To assess growth in vivo, graded numbers of either wild-type or transfected cells were implanted into the brains of CD Fischer 344 rats. No differences in survival were observed between groups of animals injected with either wild-type or transfected cells at inocula of 103 or 104 respectively. In addition, one-third of animals (7/21) challenged with 105 or 106 transfected cells survived > 50 days compared to O{\%} of animals (0/12) challenged with 105 or 106 wild-type cells. Such an effect suggests greater immunogenicity of transfected cells, but only at the larger inocula. Since C6 glioma cells will grow in both outbred and inbred strains, our model should have a number of applications including the in vivo study of EGFR targeting for glioma therapy.",
author = "Fenstermaker, {R. A.} and J. Capala and Barth, {R. F.} and A. Hujer and Hsing-Jien Kung and Kaetzel, {D. M.}",
year = "1995",
language = "English (US)",
volume = "9",
journal = "Leukemia",
issn = "0887-6924",
publisher = "Nature Publishing Group",
number = "SUPPL. 1",

}

TY - JOUR

T1 - The effect of epidermal growth factor receptor (EGFR) expression on in vivo growth of rat C6 glioma cells

AU - Fenstermaker, R. A.

AU - Capala, J.

AU - Barth, R. F.

AU - Hujer, A.

AU - Kung, Hsing-Jien

AU - Kaetzel, D. M.

PY - 1995

Y1 - 1995

N2 - The discovery of EGFR gene amplification in glioblastoma multiforme has prompted interest in experimental therapies to target the receptor on brain tumor cells. To develop an animal model for in vivo study of such strategies, we transfected C6 glioma cells with a plasmid containing the neomycin resistance gene and the human EGFR gene under the control of the glucocorticoid-inducible MMTV promoter. Following selection with G418, individual clones that expressed EGFR at high levels were selected. Kinetics of EGF binding fit a dual site model indicating the presence of both high (K(A) = 2.5 x 109 M-1) and low (K(A) = 3.3 x 107 M-1) affinity receptors. To assess growth in vivo, graded numbers of either wild-type or transfected cells were implanted into the brains of CD Fischer 344 rats. No differences in survival were observed between groups of animals injected with either wild-type or transfected cells at inocula of 103 or 104 respectively. In addition, one-third of animals (7/21) challenged with 105 or 106 transfected cells survived > 50 days compared to O% of animals (0/12) challenged with 105 or 106 wild-type cells. Such an effect suggests greater immunogenicity of transfected cells, but only at the larger inocula. Since C6 glioma cells will grow in both outbred and inbred strains, our model should have a number of applications including the in vivo study of EGFR targeting for glioma therapy.

AB - The discovery of EGFR gene amplification in glioblastoma multiforme has prompted interest in experimental therapies to target the receptor on brain tumor cells. To develop an animal model for in vivo study of such strategies, we transfected C6 glioma cells with a plasmid containing the neomycin resistance gene and the human EGFR gene under the control of the glucocorticoid-inducible MMTV promoter. Following selection with G418, individual clones that expressed EGFR at high levels were selected. Kinetics of EGF binding fit a dual site model indicating the presence of both high (K(A) = 2.5 x 109 M-1) and low (K(A) = 3.3 x 107 M-1) affinity receptors. To assess growth in vivo, graded numbers of either wild-type or transfected cells were implanted into the brains of CD Fischer 344 rats. No differences in survival were observed between groups of animals injected with either wild-type or transfected cells at inocula of 103 or 104 respectively. In addition, one-third of animals (7/21) challenged with 105 or 106 transfected cells survived > 50 days compared to O% of animals (0/12) challenged with 105 or 106 wild-type cells. Such an effect suggests greater immunogenicity of transfected cells, but only at the larger inocula. Since C6 glioma cells will grow in both outbred and inbred strains, our model should have a number of applications including the in vivo study of EGFR targeting for glioma therapy.

UR - http://www.scopus.com/inward/record.url?scp=0028858260&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028858260&partnerID=8YFLogxK

M3 - Article

VL - 9

JO - Leukemia

JF - Leukemia

SN - 0887-6924

IS - SUPPL. 1

ER -